Year None20212020201920182017 May 17, 2021 F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update PDF Version May 10, 2021 F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021 PDF Version May 07, 2021 F-star Therapeutics, Inc. Announces Pricing of $65 Million Public Offering of Common Stock PDF Version May 06, 2021 F-star Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PDF Version Apr 29, 2021 Cancer Trial Highlights Potential for Checkpoint Inhibitors Apr 19, 2021 Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy PDF Version Apr 10, 2021 F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster PDF Version Apr 01, 2021 F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration PDF Version Mar 29, 2021 F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update PDF Version Mar 16, 2021 F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021 PDF Version Pagination Current page 1 Page 2 Next page Next
